We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi Inks Deal With Korea’s ABL Bio to Develop Candidates for Neurodegenerative Diseases
Sanofi Inks Deal With Korea’s ABL Bio to Develop Candidates for Neurodegenerative Diseases
Sanofi has agreed to buy exclusive global rights to develop Korean company ABL Bio’s preclinical antibody for the treatment of neurodegenerative conditions, including Parkinson’s disease. Purchase price: $75 million upfront, with additional payments that could total $1 billion.